Keith A Rodvold
Overview
Explore the profile of Keith A Rodvold including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
100
Citations
3293
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Validity of 2020 vancomycin consensus recommendations and further guidance for practical application
Rybak M, Le J, Lodise T, Levine D, Bradley J, Liu C, et al.
Am J Health Syst Pharm
. 2021 Mar;
78(15):1364-1367.
PMID: 33764403
No abstract available.
12.
Rybak M, Le J, Lodise T, Levine D, Bradley J, Liu C, et al.
Clin Infect Dis
. 2020 Nov;
73(7):e1777-e1778.
PMID: 33238295
No abstract available.
13.
Rybak M, Le J, Lodise T, Levine D, Bradley J, Liu C, et al.
Clin Infect Dis
. 2020 Jul;
71(6):1361-1364.
PMID: 32658968
Recent clinical data on vancomycin pharmacokinetics and pharmacodynamics suggest a reevaluation of current dosing and monitoring recommendations. The previous 2009 vancomycin consensus guidelines recommend trough monitoring as a surrogate marker...
14.
Rybak M, Le J, Lodise T, Levine D, Bradley J, Liu C, et al.
Pharmacotherapy
. 2020 Apr;
40(4):363-367.
PMID: 32227354
Background: Recent vancomycin PK/PD and toxicodynamic studies enable a reassessment of the current dosing and monitoring guideline in an attempt to further optimize the efficacy and safety of vancomycin therapy....
15.
Rybak M, Le J, Lodise T, Levine D, Bradley J, Liu C, et al.
Am J Health Syst Pharm
. 2020 Mar;
77(11):835-864.
PMID: 32191793
No abstract available.
16.
Rodvold K, Burgos R, Tan X, Pai M
Clin Pharmacokinet
. 2019 Nov;
59(4):409-425.
PMID: 31773505
Omadacycline is a novel aminomethylcycline antibiotic (antibacterial). Omadacycline has had chemical structure modifications at the C9 and C7 positions of the core tetracycline rings that allow stability in the efflux...
17.
Pogue J, Jones R, Bradley J, Andes D, Bhavnani S, Drusano G, et al.
Antimicrob Agents Chemother
. 2019 Nov;
64(2).
PMID: 31767718
The polymyxins are important agents for carbapenem-resistant Gram-negative bacilli. The United States Committee on Antimicrobial Susceptibility Testing breakpoint recommendations for colistin and polymyxin B are that isolates of , ,...
18.
Rodvold K, Pai M
Clin Infect Dis
. 2019 Aug;
69(Suppl 1):S16-S22.
PMID: 31367744
Oral and intravenous (IV) omadacycline formulations are approved in the United States for treating acute bacterial skin and skin structure infections and community-acquired bacterial pneumonia in adults. Oral omadacycline bioavailability...
19.
Burgos R, Rodvold K
Infect Drug Resist
. 2019 Jul;
12:1895-1915.
PMID: 31308710
Tetracyclines have come a long way since they became available almost seven decades ago, with numerous enhancements allowing new agents to overcome bacterial mechanisms of resistance. However, these enhancements come...
20.
Sharland M, Rodvold K, Tucker H, Baillon-Plot N, Tawadrous M, Hickman M, et al.
Pediatr Infect Dis J
. 2019 Jun;
38(7):710-715.
PMID: 31192975
Background: The need for antimicrobial therapies effective against multidrug resistant organisms for children remains unmet. Tigecycline shows antibacterial activity across a broad spectrum of bacteria and is approved for treating...